Abstract:AIMS:We conducted a presentation on an 84-year-old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR-CM). In order to establish its pathogenicity, we extensively investigated the biochemical and biophysical properties of the condition. METHODS AND RESULTS:Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly acknowledged progressive infiltrative cardiomyopathy that leads to heart failure and potentially fatal arrhythmias. Gaining a comprehensive understanding of the biochemical and biophysical characteristics of genetically mutated TTR proteins serves as the fundamental cornerstone for delivering precise medical care to individuals affected by ATTR. Laboratory assessments indicated a brain natriuretic peptide of 200.12 ng/L (normal range: 0-100 ng/L) and high-sensitivity cardiac troponin I of 0.189 μg/L (normal range: 0-0.1 μg/L). Echocardiography identified left atrial enlargement, symmetrical left ventricular hypertrophy (16 mm septal and 16 mm posterior wall), and a left ventricular ejection fraction of 56%. Cardiac-enhanced magnetic resonance imaging revealed subendocardial late gadolinium enhancement. Tc-99m-PYP nuclear scintigraphy confirmed grade 3 myocardial uptake, showing an increased heart-to-contralateral ratio (H/CL = 2.33). Genetic testing revealed a heterozygous missense mutation in the TTR gene (c.302C>T), resulting in an alanine-to-valine residue change (p. Ala81Val, following the first 20 residues of signal sequence nomenclature). Biochemical analysis of this variant displayed compromised kinetic stability in both the TTRA81V:WT (wild-type) heterozygote protein (half-life, t1/2 = 21 h) and the TTRA81V homozygote protein (t1/2 = 17.5 h). The kinetic stability fell between that of the TTRWT (t1/2 = 42 h) and the early-onset TTRL55P mutation (t1/2 = 4.4 h), indicating the patient's late-onset condition. Kinetic stabilizers (Tafamidis, Diflunisal, and AG10) all exhibited the capacity to inhibit TTRA81V acid- and mechanical force-induced fibril formation, albeit less effectively than with TTRWT. Chromatographic assessment of the patient's serum TTR tetramers indicated a slightly lower concentration (3.0 μM) before oral administration of Tafamidis compared with the normal range (3.6-7.2 μM). CONCLUSIONS:We identified a patient with hATTR-CM who possesses a rare TTRA81V mutation solely associated with cardiac complications. The slightly reduced kinetic stability of this mutation indicates its late-onset nature and contributes to the gradual progression of the disease.

Inconsistency Between Hepatic Expression and Serum Concentration of Transthyretin in Mice Humanized at the Transthyretin Locus.

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells

Identification and characterization of mouse TRMU gene encoding the mitochondrial 5-methylaminomethyl-2-thiouridylate-methyltransferase.

Abstract 11641: The Role of Inflammation in a Humanized Mouse Model of Transthyretin Cardiac Amyloidosis

TTR exon-humanized mouse optimal for verifying new therapies for FAP

Establishment of Hamster- and Human-Prnp Transgenic Mice.

The mouse mutation "thrombocytopenia and cardiomyopathy" (trac) disrupts Abcg5: a spontaneous single gene model for human hereditary phytosterolemia/sitosterolemia

Differential Modification of Cys10 Alters Transthyretin's Effect on Beta-Amyloid Aggregation and Toxicity

Biochemical and Biophysical Properties of a Rare TTRA81V Mutation Causing Mild Transthyretin Amyloid Cardiomyopathy

Biochemical and Biophysical Properties of an Unreported T96R Mutation Causing Transthyretin Cardiac Amyloidosis

Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation

Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype

Transthyretin mutagenesis: impact on amyloidogenesis and disease

Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation

Characterization of Non-amyloidogenic G101S Transthyretin

The Transthyretin Gene is Expressed in Schwann Cells of Peripheral Nerves

Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy

Abstract 14427: Differences in Molecular Phenotype in Mouse and Human Hypertrophic Cardiomyopathy Suggest Need for Precision Medicine Approach to Treatment Based on Human Studies

Establishment of two cardiac-specific human cardiac troponin C mutation transgenic mice and comparative analysis

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)